Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733379 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL27921629 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL826108 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL825730 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL531229 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL531066 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL3505565 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL965875 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL826118 | 1.00 | SMPD1 (0.50) | SMPD1TSHRTHRBLMNADNM1 | |
| SCHEMBL167839 | 0.97 | SMPD1 (0.46) | SMPD1TSHRTHRBLMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496370-B2 | Freshening compositions comprising controlled release modulators | Arylessence, Inc. (US) | 2025-12-16 | — | — | US | claimed |
| CN-119114033-A | Low-protein-adsorptivity blood perfusion adsorbent, preparation method thereof and blood perfusion device | 泉州师范学院 | 2024-12-13 | — | — | CN | claimed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| US-11806448-B2 | Freshening compositions comprising controlled release modulators | Arylessence, Inc. (US) | 2023-11-07 | — | — | US | claimed |
| EP-2094737-A1 | CATALYST COMPONENT FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia S.r.l. (IT) | 2009-09-02 | — | — | EP | claimed |
| WO-2008061662-A1 | CATALYST COMPONENT FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2008-05-29 | — | — | WO | claimed |
| US-5626852-A | HYDROLYSIS OF ACETAL AND/OR KETAL | THE MENNEN COMPANY (US) | 1997-05-06 | — | — | US | claimed |
| JP-63297376-A | — | — | None | — | — | JP | disclosed |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069734-A1 | FRESHENING COMPOSITIONS COMPRISING CONTROLLED RELEASE MODULATORS | ARYLESSENCE INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260028554-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES | OSMO LABS PBC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12496370-B2 | Freshening compositions comprising controlled release modulators | Arylessence, Inc. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250313523-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS, PBC | 2025-10-09 | — | — | US | disclosed |
| US-6211416-B1 | REACTING ACETAL OR KETAL WITH ACETYLENE OR ALLENE IN GAS PHASE IN PRESENCE OF CATALYST SELECTED FROM ZINC- OR CADMIUM-SILICON- AND OXYGEN-CONTAINING HETEROGENEOUS CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-03 | — | — | US | disclosed |
| CN-1261341-A | Method for producing end ethers | BASF AG (DE) | 2000-07-26 | — | — | CN | disclosed |
| EP-0703211-B1 | Process for the preparation of unsaturated ethers | DEGUSSA (DE) | 1999-11-10 | — | — | EP | disclosed |
| US-5576465-A | DEHYDROETHERIFICATION OF ACETALS OR KETALS BY HEATING | HUELS AKTIENGESELLSCHAFT (DE) | 1996-11-19 | — | — | US | disclosed |
| EP-0703211-A1 | Process for the preparation of unsaturated ethers | HÜLS AKTIENGESELLSCHAFT (DE) | 1996-03-27 | — | — | EP | disclosed |
| WO-1995006025-A1 | PROCESS FOR THE PREPARATION OF AN ACETAL | DSM N.V. (NL) | 1995-03-02 | — | — | WO | disclosed |
| JP-S63297376-A | PRODUCTION OF 1,3-DITHIANE DERIVATIVE | NITTO KASEI KK | 1988-12-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313523-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CYP8B1, CYP1B1, BBOX1 | SMPD1 3917/4885TSHR 4274/4885THRB 1397/4885 |
| US-20260028554-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES | TAS2R42, TAS2R4, TAS2R41 | SMPD1 2783/4885TSHR 2405/4885THRB 2294/4885 |
| US-20260069734-A1 | FRESHENING COMPOSITIONS COMPRISING CONTROLLED RELEASE MODULATORS | FFAR1, FFAR2, FFAR3 | SMPD1 1113/4885TSHR 1822/4885THRB 2433/4885 |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | SMPD1 3008/4885TSHR 1119/4885THRB 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.